ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company developing treatments for mental health disorders. Its lead compounds include PCN-101, a subcutaneous R-ketamine for treatment-resistant depression; RL-007, a modulator for cognitive impairment in schizophrenia; DMX-1002, an oral ibogaine for opioid use disorder; GRX-917, an oral deuterated etifoxine for generalized anxiety disorder; and NN-101, an intranasal N-acetylcysteine for mild traumatic brain injuries. Other candidates include VLS-01 for depression and EMP-01 for PTSD. The ATAI YTD return is shown above.
The YTD Return on the ATAI YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ATAI YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ATAI YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|